Premium
Splenectomy during chronic lymphocytic leukemia
Author(s) -
Pegourie Brigitte,
Sotto JeanJacques,
Hollard Daniel,
Michallet Mauricette,
Sotto MarieFrance
Publication year - 1987
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19870501)59:9<1626::aid-cncr2820590917>3.0.co;2-w
Subject(s) - splenectomy , medicine , chlorambucil , chronic lymphocytic leukemia , surgery , gastroenterology , lymphocytic infiltration , spleen , infiltration (hvac) , leukemia , chemotherapy , cyclophosphamide , physics , thermodynamics
The combination of discontinuous high‐dose chlorambucil therapy with splenectomy greatly increased the prognosis of aggressive forms of chronic lymphocytic leukemia (CLL). The median survival for 43 patients was 84 months from diagnosis and 48 months from splenectomy. For 15 stage 0, according to Rai classification, obtained after splenectomy, duration ranged from 3 to 105 months. The median survival of a group of patients showing “nodular splenic infiltration” was 104 months and superior to that of a group of patients showing “diffuse splenic infiltration” (72 months). In four of 15 cases studied, the peripheral blood lymphocytic clone disappeared after splenectomy.